|4Oct 19, 5:23 PM ET

WYETH 4

4 · WYETH · Filed Oct 19, 2009

Insider Transaction Report

Form 4
Period: 2009-10-15
Peppard Denise M.
Sr. VP Human Resources
Transactions
  • Disposition to Issuer

    Common Stock

    2009-10-15$49.58/sh18,220$903,34812,526 total
  • Disposition to Issuer

    Employee Stock Option

    2009-10-1520,0000 total
    Exercise: $56.52Common Stock (20,000 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$6.01/sh8,597$51,6680 total
    Exercise: $43.57Common Stock (8,597 underlying)
  • Disposition to Issuer

    Common Stock

    2009-10-1512,5260 total
  • Disposition to Issuer

    Employee Stock Option

    2009-10-1530,0000 total
    Exercise: $60.70Common Stock (30,000 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$1.36/sh17,194$23,3840 total
    Exercise: $48.22Common Stock (17,194 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$5.02/sh52,000$261,0400 total
    Exercise: $44.56Common Stock (52,000 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-157,1000 total
    Exercise: $56.59Common Stock (7,100 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$14.90/sh1$150 total
    Exercise: $34.67Common Stock (1 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-1525,7900 total
    Exercise: $56.00Common Stock (25,790 underlying)
Footnotes (5)
  • [F1]Represents restricted stock units.
  • [F2]Pursuant to the Agreement and Plan of Merger by and among Wyeth, Pfizer Inc. and Wagner Acquisition Corp., dated as of January 25, 2009 (as amended, the "Merger Agreement"), each restricted stock unit was cancelled at the effective time of the merger in exchange for cash equal to the per share value of the merger consideration of $49.58, less any applicable tax withholding.
  • [F3]Represents Wyeth common stock.
  • [F4]Pursuant to the Merger Agreement, each of these shares was cancelled at the effective time of the merger and converted into the right to receive $33.00 in cash and 0.985 of a share of Pfizer Inc. common stock, less any applicable tax withholding.
  • [F5]Pursuant to the Merger Agreement, each outstanding and unexercised option, whether vested or unvested, was cancelled at the effective time of the merger in exchange for cash equal to the product of (a) the number of shares underlying such option and (b) the excess, if any, of the per share value of the merger consideration of $49.58 over the per share exercise price of the option, less any applicable tax withholding.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION